Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18047506 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | Final Rejection | Hoffmann-La Roche Inc. |
| 17786239 | SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Final Rejection | BRISTOL-MYERS SQUIBB COMPANY |
| 17781406 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | Final Rejection | THE TRUSTEES OF DARTMOUTH COLLEGE |
| 18029057 | MULTI-COORDINATE GOLD-PHOSPHINE COMPOUNDS AND METHOD OF USE | Non-Final OA | University of Kentucky Research Foundation |
| 18498472 | METHOD OF INHIBITING LIPOGENESIS WITH UBIQUITIN-SPECIFIC PEPTIDASE 24 INHIBITOR COMPOSITION | Non-Final OA | NATIONAL CHENG KUNG UNIVERSITY |
| 17709358 | USE OF COMPOSITION OF IMATINIB OR DERIVATIVE THEREOF IN PREPARATION OF DRUG FOR PREVENTING, TREATING, AND CONTROLLING ADDICTION RELAPSE | Final Rejection | Wuhan University |
| 18576998 | INSECTICIDAL MIXTURES | Non-Final OA | ADAMA MAKHTESHIM LTD. |
| 18413628 | CLEAN BEAUTY EMULSIFICATION SYSTEM | Non-Final OA | AMOREPACIFIC CORPORATION |
| 17889062 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Final Rejection | NURIX THERAPEUTICS, INC. |
| 18573359 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | Non-Final OA | LDN Pharma Limited |
| 18545582 | SULFOXIMIDE SUBSTITUTED INDAZOLE IRAK4 KINASE INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | Non-Final OA | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. |
| 18560696 | APPLICATION OF HYDRONIDONE IN PREPARATION OF DRUG FOR TREATING OR PREVENTING CHRONIC HEPATITIS B WITH LIVER FIBROSIS | Non-Final OA | BEIJING CONTINENT PHARMACEUTICALS CO., LTD. |
| 17907463 | COMPOUNDS AND USES THEREOF | Non-Final OA | Foghorn Therapeutics Inc. |
| 18563568 | THIADIAZOLIDINONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | Non-Final OA | ADMINISTRACIÓN GENERAL DE LA COMUNIDAD AUTÓNOMA DE EUSKADI |
| 18012561 | MMP-9 AND MMP-12 INHIBITION FOR TREATING SPINAL CORD INJURY OR RELATED INJURY TO NEUROLOGICAL TISSUE | Final Rejection | The University of Birmingham |
| 18373904 | TREATMENT OF MENTAL DISORDERS | Non-Final OA | GH Research Ireland Limited |
| 18255476 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | Non-Final OA | IMPACT THERAPEUTICS (SHANGHAI), INC |
| 18283121 | COMPOUND HAVING SULFONATE GROUP AND PHOTOELECTRIC CONVERSION ELEMENT USING SAME | Non-Final OA | HODOGAYA CHEMICAL CO., LTD. |
| 18551059 | TASIPIMIDINE FORMULATIONS AND USE THEREOF | Non-Final OA | ORION CORPORATION |
| 18550958 | New 5,6,7,8-Tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one Derivatives as Sigma Ligands | Non-Final OA | ACONDICIONAMIENTO TARRASENSE |
| 18011741 | Crystalline Form of Compound | Non-Final OA | Shenzhen Forward Pharmaceuticals Co., Limited |
| 18262231 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Final Rejection | VERNALIS (R&D) LTD |
| 18043419 | COMPOUND FOR INHIBITING MUTANT EGFR AND USE THEREOF | Non-Final OA | East China University of Science and Technology |
| 18250853 | PROCESS FOR PREPARATION OF PURE NALTREXONE DECANOATE, ITS SALTS, COMPOSITION AND METHOD OF USE THEREOF | Final Rejection | NAVIN SAXENA RESEARCH & TECHNOLOGY PVT. LTD. |
| 18131979 | USE OF HISTONE ACETYLTRANSFERASE INHIBITOR AMIDOXIMES AS ANTI-PROLIFERATIVE AGENTS | Non-Final OA | Texas Woman’s University |
| 17941854 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Final Rejection | SERVIER PHARMACEUTICALS LLC |
| 18246034 | NOVEL N-HETEROCYCLIC BET BROMODOMAIN INHIBITOR, AND PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | Non-Final OA | Chengdu Easton Biopharmaceuticals Co., Ltd. |
| 17906650 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | Final Rejection | Akebia Therapeutics, Inc. |
| 17626486 | INHIBITORS OF TYROSINE KINASE | Final Rejection | BridGene Biosciences, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy